In the media

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab</p>
4 Feb 2019 - La Vanguardia

La Vanguardia has published an opinion article by Roger Gomis, head of the Control of Growth and Cancer Metastasis lab at IRB Barcelona, in the framework of the World Cancer Day. In the article, the researcher gives information about the latest report from the AECC, ASEICA and the la Caixa Foundation. "In recent decades, joint action in prevention, diagnosis, surgery and new therapies has had a notable impact on patient survival, increasing from 20% to 55% today. This effect is always attributable to innovation and research seeking to transform and adapt treatments to the needs of each patient," says Gomis.

Link to...

<p>Raúl Méndez, IRB Barcelona & José J. Lucas, CSIC. Picture by Xavier Cervera, La Vanguardia.</p>
25 Jan 2019 - La Vanguardia

La Vanguardia has published an article about a research project led by IRB Barcelona and the Severo Ochoa Molecular Biology Centre that has been nominated for the "Vanguardia de la Ciencia" Award. Addressing the CPEB4 protein, the study reveals that it is a key factor in the origin of autism. The winning project will be chosen through a popular vote. The last day to vote is 28 February.

Link to La Vanguardia

<p>Lluís Ribas, group leader at IRB Barcelona</p>
18 Jan 2019 - La Sexta & other media

La Sexta and Agencia Sinc, among other media, have published an article on the recent study by IRB Barcelona, led by ICREA researcher Lluís Ribas, who has discovered a mechanism that evolved in eukaryotic cells and that facilitates the synthesis of proteins, such as those present in the extracellular matrix. Of note, some of these proteins are highly relevant in biomedicine because of their link with diseases and greater knowledge of these molecules may bring about the development of strategies to inhibit their production, according to the authors.

Link to...

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab</p>
16 Jan 2019 - El Mundo

El Mundo newspaper has published an article on a study by the University of Basel (Switzerland) that has found a way to separate the tumour cells that circulate in blood in groups and to prevent them from forming metastases. In this regard, they include the opinion of Roger Gomis, ICREA researcher at IRB Barcelona: "(This study) allows us to understand how to handle the aggregated cells that initiate the tumour, but now we need more effective and clinically optimal compounds. It is another step in a very fertile field such as the cells in circulation, but we must be realistic in terms of expectations. There is a gulf between what we see in the laboratory and what can be done with...

<p>Begoña Cánovas, postdoctoral researcher at IRB Barcelona. Source: Alma, Obra Social ”la Caixa”</p>
15 Jan 2019 -

Tot Barcelona, e-notícies and El Plural have published an interview with Begoña Cánovas, a postdoctoral researcher at IRB Barcelona, who, thanks to a grant from "la Caixa", has been part of the team of researchers that detected the protein that fuels the survival of a type of breast cancer. "The day they gave me the first fellowship, I couldn’t believe it. I felt great and my parents jumped for joy when they found out. When you see all the applications, you feel like it's a lottery and you think you have no chance of winning, but it's worth trying, "said Cánovas.

Link to e-...

<p>Source: COPE</p>
11 Jan 2019 - COPE

Cope, ABC, La Rioja, among other media, have published an article about the inscriptions to the IV Women's Race for Research from Asociación Española Contra el Cáncer (AECC). The resources obtained from this race will be used to finance two predoctoral grants at two institutions in La Rioja. Also, the project "Research on the impact of senescence influenced by inflammation as a therapy on cancer stem cells" led by Marta Kovatcheva, researcher at IRB Barcelona, will be financed.

Link to Cope

...
<p>Giant Yellow Israeli scorpion. Image: Ester Inbar</p>
8 Jan 2019 - Radio 5 (RNE)

RNE's "Inquietamente" programme has interviewed Meritxell Teixidó, IRB Barcelona research associate, about the study based on scorpion venom. "We saw that there was a peptide in the scorpion venom, chlorotoxin, which has the ability to reach the central nervous system and then act as toxin, "said Teixidó.

Link to RNE

 

<p>Quo magazine cover</p>
31 Dec 2018 - QUO

Quo magazine has published a report on the aesthetic treatments that people use to stay young. They mention, for example, Botox, red light masks, breast prostheses, among others. In the article, they include the statements of experts in the field of health and research and also mention the study performed by IRB Barcelona and CNAG-CRG on the aging of the skin caused by the loss of identity and function of the main cells of the dermis.

 

<p>A invasive front of highly aggressive tumour cells (in green). Confocal microscopy image. Alexandra Avgustinova, IRB Barcelona.</p>
28 Dec 2018 - Hidden Nature

The web Hidden Nature has published an article about the 10 investigations that they considered to be the most important ones published in 2018. One of them refers to epigenetic therapies and mentions research research that supports and rejects them. In this regard, they mention the study led by Salvador Aznar Benitah at IRB Barcelona and published in Nature Cell Biology. The study in question concludes that care must be taken with drugs that inhibit epigenetic factors as they could cause the appearance of aggressive tumours.

Link to Hidden Nature

<p>A invasive front of highly aggressive tumour cells (in green). Confocal microscopy image. Alexandra Avgustinova, IRB Barcelona.</p>
20 Dec 2018 -

The journal Biocentury Innovations has published an article on the study led by IRB Barcelona researchers Salvador Aznar Benitah and Fran Supek and first-authored by postdoctoral researcher Alexandra Avgustinova. The study has shown that increasing chromatin accessibility in cancer promotes tumour aggressiveness and does not reduce tumour mutation burden, as previously believed. The article refers to one of the main conclusions of the study, namely the need to evaluate the long-term effects of chromatin modifiers in tumour models before taking them into the clinic.